Final Rule on Meaningful Use Offers More Flexibility for Docs

Article

The final rule on the definition and requirements for demonstrating meaningful use of EHRs to qualify for federal incentives has been issued, and for doctors, it means more flexibility.

Healthcare professionals voiced their concerns, and rule makers listened.

At 10 a.m. EST this morning, the Office of the National Coordinator for Health Information Technology (ONC) issued a final rule on the definition and requirements for demonstrating meaningful use of EHRs to qualify for incentive payments under the HITECH Act.

The final regulations include several medications designed to provide more flexibility and multiple pathways for those charged with meeting meaningful use requirements. The changes, said David Blumenthal, MD, the National Coordinator for Health IT, were made in response to the 2,000-plus comments that were received in regard to the proposed rule, which was issued in December of 2009.

In particular, it was “concerns about the pace and scope of implementation of meaningful use” that led rule makers to “adopt a two-track approach regarding the objectives that allow practices and hospitals to qualify for incentive payments in the first 2 years of the program,” wrote Blumenthal and Marilyn Tavenner, RN, in an article published today in the New England Journal of Medicine.

The final rule outlines the specific criteria that must be met to achieve stage 1 meaningful use, and the clinical quality measure reporting requirements needed to receive incentive payments in 2011 and 2012 (the 864-page document is available here through the Office of the Federal Register).

The most notable changes to the proposed rule include the following:

• The number of quality measures that has to be met has been reduced to 44 (physicians must meet six of those objectives, and hospitals must meet 15)

• The number of measures required to demonstrate that EHRs are being used in a meaningful way has been reduced to 15 for physicians and 14 for hospitals

• The number of clinical decision support requirements has been reduced from five to one (for stage 1)

• The percentage of prescriptions that need to be sent electronically has decreased from 75% to 40%

In addition, some of the meaningful use quality reporting measures are being deferred to stage 2.

“The rule was too inflexible,” said Blumenthal during the press conference. Visit HCPLive.com later today and in the weeks ahead for more information on the final rule.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Edward V Loftus, Jr, MD | Credit: Mayo Clinic
Connective Tissue Disease Brings Dermatology & Rheumatology Together
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.